Introduction {#s1}
============

Chronic urticaria, defined as urticaria with episodes extending for more than 6 weeks [@pone.0023931-Zuberbier1], is a relatively common condition from which 0.5--1% of the population suffers at any single time [@pone.0023931-Maurer1] with all age groups and social strata affected. Furthermore, epidemiological studies have shown that this condition, which may last for months or even years [@pone.0023931-vanderValk1], [@pone.0023931-Toubi1] may lead to major detrimental effects on quality of life, sleep deprivation and be associated with mental illness [@pone.0023931-ODonnell1]--[@pone.0023931-Grob1]. As a consequence, effective therapy is of paramount importance.

The guidelines issued following the third international consensus meeting on urticaria in 2008, a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the EU-funded network of excellence, the Global Allergy and Asthma European Network (GA^2^LEN), the European Dermatology Forum (EDF) and the World Allergy Organization (WAO) [@pone.0023931-Zuberbier2], recommended that the first line treatment for chronic urticaria should be second generation, non-sedating H~1~-antihistamines. There is a positive recommendation against the routine use of old sedating first generation antihistamines. If standard dosing is not effective, increasing the dosage of non-sedating H~1~-antihistamines up to four-fold is recommended. Only if patients do not respond to this four-fold increase in dosage it is recommended that second-line therapies should be added to the antihistamine treatment. While many dermatologists use up-dosing regularly, the justification for it is based on long-standing clinical experience rather than good scientific evidence. It is only more recently that clinical trials have been performed to assess the response of H~1~-antihistamines at two times [@pone.0023931-Zuberbier3]--[@pone.0023931-Metz1], three times [@pone.0023931-Asero1], [@pone.0023931-Godse1] and four times [@pone.0023931-Siebenhaar1], [@pone.0023931-Staevska1] the licensed dose. However, what still remains to be done is to assess how patients view up-dosing with H~1~-antihistamines.

In this study, we have used a questionnaire to ask 319 patients with chronic spontaneous urticaria about the course of their condition, their previous treatment and its effectiveness with a special focus on their experience with up-dosing with H~1~-antihistamines. The results demonstrate that the patients rate second generation antihistamines to be more effective and better tolerated than first generation drugs and that many patients benefit from increasing the dose up to fourfold in case the standard licensed dose is not capable to adequately control their symptoms.

Methods {#s2}
=======

Objectives {#s2a}
----------

The main objective of this study was to assess the effectiveness and side effects of sedating vs. non-sedating H~1~-antihistamines as well as of non-sedating H~1~-antihistamines in standard vs. higher than standard doses from the patients\' perspective.

Procedures and Participants {#s2b}
---------------------------

This was a questionnaire based retrospective survey initially completed by 368 individuals of whom 319 had a positive diagnosis of chronic spontaneous urticaria and were included in the [results](#s3){ref-type="sec"}. Of these, 121 received questionnaires from their hospital or physician and 198 learnt about the survey on the internet from either the homepage of Allergie-Centrum-Charité or the web page of the Urticaria Network e.V. ([www.urtikaria.net](http://www.urtikaria.net)). The latter group completed the questionnaire online. Both physician administered and on-line questionnaires were identical. All questionnaires were completed anonymously and no Internet Protocol (IP) addresses were saved. Individuals from all 16 Federal States of Germany, 36% from rural areas, 38% from urban areas and 26% from metropolitan areas participated in the study. The only prerequisite for participation was that the individuals suffered from chronic spontaneous urticaria (recurrent spontaneous occuring wheals for \>6 weeks) and were adults of age 18 or older. In addition, all participants were asked, if their urticaria was diagnosed by a physician (response options "yes" and "no"). Only those subjects who responded with "yes" were included in the analysis.

Ethics {#s2c}
------

All participants received a patient information sheet before participation. To assure the full anonymity of the data set formal written informed consent was not obtained. However, the patient information contained a passage informing the participants that they declare their consent by completing the questionnaire. The survey and the indirect method of obtaining patient consent were both approved by the ethics committee (Ethikkommission der Charité - Universitätsmedizin Berlin, EA1/200/09) and the data protection commissioner of the Charité -- Universitätsmedizin, Berlin.

Data and Statistics {#s2d}
-------------------

The data collected by this retrospective patient survey included the following: epidemiology and method of securing of the diagnosis, details of previous and current therapy, reasons for changing therapies, and experience with up-dosing with H~1~-antihistamines. In total, the questionnaire consisted of 54 questions, mostly involving Likert-scale ratings, quantitative questions, yes/no lists and multiple choice questions (the questionnaire can be provided upon request). The questions were assigned to the following subheadings: 1) general information (on the participants), 2) questions concerning the symptoms and course of disease, 3) questions concerning the diagnosis of urticaria, 4) questions concerning the treatment of urticaria, 5) questions concerning the impact of urticaria and 6) questions regarding care and the physician patient relationship. For the questions relevant to this manuscript, no time frame was specified in order to obtain as much patient experience as possible. Differences between first and second generation H~1~-antihistamines and standard and high dose therapy were tested using Fishers exact test.

Results {#s3}
=======

Patient details {#s3a}
---------------

The 319 respondents included in the survey (248 female and 71 male) of median age 42 years (range 18 to 76 years) stated that they had symptoms consistent with chronic spontaneous urticaria and had their diagnosis confirmed by a physician. Of the physicians who confirmed the diagnosis, 70% were dermatologists. The mean duration of the respondents\' urticaria since diagnosis was 70±6 months (mean ± SEM) with wheals occurring daily in 48% of patients and several times a month in 95% of patients. Individual wheals lasted less than 24 hours in 87% of patients. Of the respondents, 25% rated their symptoms as moderate-to-severe, 46% as severe and 25% rated them as very severe. Furthermore, 68% reported that they also had symptoms of angioedema and 71% could not identify a cause for urticaria.

Spectrum of H~1~-antihistamines used {#s3b}
------------------------------------

The patients in the survey stated that they had taken at least one of twelve H~1~-antihistamines from a given list, of which four, clemastine, dimethindene, hydroxyzine and promethazine, were first generation 'sedating' antihistamines and eight, cetirizine, desloratadine, ebastine, fexofenadine, levocetirizine, loratadine, mizolastine, rupatadine, were second generation, 'non-sedating' antihistamines ([**Figure 1**](#pone-0023931-g001){ref-type="fig"}).

![The spectrum of H~1~-antihistamines taken by the patients for the treatment of their chronic spontaneous urticaria.\
The results are expressed as the total number of participants who reported information on the efficacy of the itemized antihistamines in regular dose.](pone.0023931.g001){#pone-0023931-g001}

Altogether, 205 respondents reported a total of 322 changes from one antihistamine to another during progression of their disease. The reason for changing medication was stated 230 times to be due to lack of effectiveness and 87 times due to side effects.

First versus second generation H~1~-antihistamines {#s3c}
--------------------------------------------------

The patients\' perspective of the comparative efficacy of first and second generation H~1~-antihistamines taken at the standard dose (manufacturers recommended or licensed dose) is shown in [**Figure 2**](#pone-0023931-g002){ref-type="fig"}. For statistical comparisons, the responses were divided into two groups; significant improvement or complete freedom from symptoms and slight or no improvement. The results ([**Table 1**](#pone-0023931-t001){ref-type="table"}) show that the patients believed second generation antihistamines to be significantly (*P*\<0.005) more effective than first generation drugs.

![The comparative efficacy first and second generation H~1~-antihistamines in chronic spontaneous urticaria.\
The histograms were constructed from 147 and 721 patient reports respectively.](pone.0023931.g002){#pone-0023931-g002}
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###### Comparison of first and second generation H~1~-antihistamines in chronic spontaneous urticaria.

![](pone.0023931.t001){#pone-0023931-t001-1}

                                      First generation   Second generation   Significance of Difference
  ---------------------------------- ------------------ ------------------- ----------------------------
  **Effectiveness:**                                                        
  Significant or total improvement         15.6%               26.8%        
  Slight or no improvement                 84.4%               73.2%                 *P*\<0.005
                                         (n = 147)           (n = 721)      
  **Unwanted Effects:**                                                     
  Unwanted Effects                         46.5%               31.6%                 *P*\<0.001
  Sedation                                 38.9%               22.7%                 *P*\<0.001
                                         (n = 157)           (n = 699)      

The first generation 'sedating' antihistamines were clemastine, dimethindene, hydroxyzine and promethazine and the second generation, 'non-sedating' antihistamines were cetirizine, desloratadine, ebastine, fexofenadine, levocetirizine, loratadine, mizolastine and rupatadine. All were taken at the standard licensed dose. Statistical comparisons were made using Fisher\'s exact test. n indicates the number of reports received for each condition.

The patients were also asked whether or not taking a standard dose of H~1~-antihistamines caused unwanted effects. The responses ([**Table 1**](#pone-0023931-t001){ref-type="table"}) showed first generation antihistamines to cause significantly (*P*\<0.001) more unwanted effects than second generation drugs. Furthermore, more respondents stated that they felt tired when taking first generation antihistamines compared with second generation drugs. Again, the difference was highly significant (*P*\<0.001).

Up-dosing with H~1~-antihistamines {#s3d}
----------------------------------

A total of 238 of the 319 patients (75%) in the survey stated that they had increased their daily dose of antihistamine to two, three or four tablets daily. Of these, 216 (68%) of the patients stated that they had taken this course of action because of the lack of effectiveness when taking a standard dose. [**Figure 3**](#pone-0023931-g003){ref-type="fig"} shows the effectiveness of up-dosing with second generation H~1~-antihistamines. Of the reports from individuals who had stated that they had up-dosed, 40%, 42% and 54% showed significant added benefit from taking 2, 3 or 4 tablets daily rather than standard dose therapy while approximately one quarter stated that no additional benefit had been derived.

![Effectiveness of H~1~-antihistamine updosing in chronic spontaneous urticaria.\
The reported effectiveness of up-dosing with second generation H~1~-antihistamines compared with standard dose therapy in chronic spontaneous urticaria. The number of patient reports in each group are; 2 tablets = 108, 3 tablets = 72 and 4 tablets = 85.](pone.0023931.g003){#pone-0023931-g003}

Unwanted effects and concerns with up-dosing {#s3e}
--------------------------------------------

The number of reports of unwanted effects and sedation following up-dosing with second generation H~1~-antihistamines are shown in [**Table 2**](#pone-0023931-t002){ref-type="table"} and are not statistically different from those reported for the use of standard doses of antihistamines. However, of the 135 reports about unwanted effects, 85 gave also information on the magnitude at high doses in comparison to regular doses of the same second generation H~1~-antihistamine: 30 (35%) stated that the unwanted effects were considerably worse and 33 (39%) stated that they were somewhat worse.

10.1371/journal.pone.0023931.t002

###### Unwanted effects and sedation while using standard doses or up-dosing with H~1~-antihistamines in chronic spontaneous urticaria.

![](pone.0023931.t002){#pone-0023931-t002-2}

                          Standard dosage   Up-dosing    Significance of Difference
  ---------------------- ----------------- ----------- ------------------------------
  **Unwanted Effects**         31.6%          32.5%     not significant(*P* = 0.791)
                             (n = 699)      (n = 416)  
  **Sedation**                 22.7%          22.1%     not significant(*P* = 0.824)
                             (n = 699)      (n = 416)  

The reports included in this table are from patients who had taken either the standard dose or two, three or four times the standard dose each day of a second generation H~1~-antihistamine. Statistical comparisons were made using Fisher\'s exact test. n indicates the number of reports received for each condition.

Patients also expressed concerns about up-dosing with H~1~-antihistamines. Of the 319 respondents, 26% were worried about possible side effects, 23% about possible long term harmful effects, 19% about the possible loss of efficacy, 9% about becoming dependent on their medication and 3% about other unspecified effects.

Discussion {#s4}
==========

This survey shows that, from a patients\' perspective, a standard licensed dose of an H~1~-antihistamine often fails to provide adequate symptomatic relief in chronic spontaneous urticaria. This is evidenced by the reported 322 changes of medication and the finding that 75% of the respondents reported to increasing their daily dose of antihistamines in order to improve symptomatic control.

Because this survey asked questions relating to treatment over many years, many patients stated that they either had been or are being treated with first generation H~1~-antihistamines. These drugs, many of which have been available for more than 50 years, have pronounced anticholinergic effects and central nervous system sedative actions which limit the doses at which they can be given [@pone.0023931-Simons1], [@pone.0023931-Church1]. Consequently, in clinical usage for urticaria, first generation H~1~-antihistamines are generally less effective than second generation drugs [@pone.0023931-Simons2], a conclusion supported by our survey. Furthermore, it is well established that taking first generation H~1~-antihistamines in standard doses frequently leads to side effects of which daytime somnolence, sedation, drowsiness, fatigue and impaired concentration and memory are the most prominent [@pone.0023931-Simons1], [@pone.0023931-Simons3], [@pone.0023931-Simons4]. The finding in this survey that first generation H~1~-antihistamines were associated with significantly more side effects and sedation than second generation drugs supports these conclusions. These results support the recommendation in the guidelines [@pone.0023931-Zuberbier2] that the first line treatment for chronic urticaria should be second generation H~1~-antihistamines rather than the old sedating first generation H~1~-antihistamines.

Of the responses from patients taking second generation antihistamines, 23% stated that the feeling of sedation was a problem. This is considerably higher than somnolence levels cited in clinical studies [@pone.0023931-Simons3]--[@pone.0023931-Devillier1]. However, the majority of sedation studies with H~1~-antihistamines are performed in either healthy individuals or individuals with mild disease rather than in conditions, such as severe chronic urticaria, in which sleep disturbances are a major issue [@pone.0023931-Maurer2]. Thus, in surveys such as ours, it is difficult to discern what proportion of the 'sedation' reported by the patients is due to the drug and what is due to their condition.

Of the reports from individuals who had stated that they had up-dosed their H~1~-antihistamine, approximately half stated that there was a significant benefit compared with standard dose therapy while approximately one quarter stated that no additional benefit had been derived. This finding that in many cases of chronic spontaneous urticaria, therapy with H~1~-antihistamines is not sufficient, even at higher than licensed doses, confirms previous studies [@pone.0023931-Maurer1], [@pone.0023931-GimenezArnau1], [@pone.0023931-Staevska1].

Perhaps the major concern shared by both patients and doctors concerns the possibility of somnolence with up-dosing of H~1~-antihistamines. However, in this survey, the percentage of reports of sedation following up-dosing compared with standard doses of H~1~-antihistamines was not statistically different. There are two possible reasons for this. The first is that the relief from urticaria-related discomfort led to a better quality of sleep with subsequent less sedation during the day [@pone.0023931-Staevska1]. The second possibility, which is likely to occur in parallel, is the development of tolerance to the central nervous sedative effects of the antihistamines which occurs with prolonged periods of administration [@pone.0023931-Richardson1], [@pone.0023931-Verster1].

However, of the reports received following antihistamine up-dosing, many stated that unwanted effects were worse than with the standard dose. This illustrates the patient variability to the central nervous effects of second generation H~1~-antihistamines and that the blanket term of 'non-sedating' for this class of drug is not appropriate for many patients.

Strengths and limitations of this study {#s4a}
---------------------------------------

The major strengths of this study are: first, that it canvassed the opinions of patients from many walks of life from all over Germany; second, patients were only admitted after a physician had confirmed the diagnosis of chronic spontaneous urticaria; many patients had taken both first and second generation antihistamines and were, therefore, able to compare their efficacy and unwanted effects; and, fourth, three quarters of the patients had up-dosed with antihistamines. The weaknesses of the study are: first, many patients commented on drugs that they had taken many years ago and, therefore, their memory of relevant details may be a little unreliable (recall bias); second, because of the size of the cohort, co-morbidities could not be included in the analysis; and, third, due to the way of patient recruitment, a selection effect can not be excluded.

Conclusions {#s4b}
-----------

In conclusion, this survey has shown that approximately three quarters of reports indicate that patients obtain additional benefit from up-dosing with H~1~-antihistamines. Also, in approximately three quarters of responses, the reported frequency of side effects was no greater than with standard doses. Furthermore, the survey shows a clear benefit of second generation over first generation drugs in both efficacy and their side effects. These results, therefore, support the guidelines recommendations [@pone.0023931-Zuberbier2] that the first line treatment for chronic spontaneous urticaria should be second generation H~1~-antihistamines and that, if standard dosing is not effective, the dosage should be increased up to four-fold.
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